Cangene awarded U.K. contract to supply Vaccinia Immune Globulin
Cangene announced that it has been awarded a contract to supply Vaccinia Immune Globulin Intravenous (Human) ("VIG") to the U.K. Department of Health. The approximately $17 million Cdn contract was awarded to Cangene by the U.K. government. Cangene expects to complete delivery by the end of its 2006 fiscal year. Acambis plc, Cangene's VIG sales agent for territories outside North America and Israel, was instrumental in securing the contract. Cangene, in conjunction with its sales agents, is also in discussions with other foreign governments regarding a supply of VIG.
VIG is a hyperimmune product to be used in treating and preventing a type of severe reaction that may be brought on by administration of the smallpox vaccine, and is considered to be an important component of smallpox vaccination programs. Hyperimmunes are highly purified specialty antibodies made from human plasma.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.